Directory
Business & Industry
- Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD
- BlueRock Therapeutics announces publication in Nature of 18-month data from Phase 1 clinical trial for bemdaneprocel, an investigational cell therapy for Parkinson's disease
- European Commission approves Pfizer's RSV vaccine ABRYSVO® to help protect adults aged 18-59 against RSV lower respiratory tract disease
- Bayer and Puhe BioPharma enter into global license agreement for clinical phase I PRMT5 inhibitor
- AstraZeneca enters license agreement with Alteogen
Research & Development
- New technology facilitates delivery of advanced medicines
- A candidate drug dismantles a metabolic barrier to anti-tumor immunity
- Fungi dwelling on human skin may provide new antibiotics
- Unlocking a new era in liver cancer treatment: The power of neddylation-targeted therapies
- Scientists finally confirm vitamin B1 hypothesis from 1958
- Empowering antibodies to better activate the immune system
- Existing drug has potential for immune paralysis
Conferences & Events
- New insights into T and B cells offer hope for autoimmune disease sufferers
- SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
- SAE Media Group's 6th annual 3D Cell Culture Conference
- CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
- 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
- CPHI Excellence in Pharma Award Winners 2022
- CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
Regulatory Affairs
- FDA approves first gene therapy for treatment of aromatic L-amino acid decarboxylase deficiency
- FDA approves new treatment for hemophilia A or B
- FDA approves nasal spray influenza vaccine for self- or caregiver-administration
- FDA approves first nasal spray for treatment of anaphylaxis
- FDA approves nonsteroidal treatment for Duchenne muscular dystrophy